C
Christine B. Turley
Researcher at University of South Carolina
Publications - 26
Citations - 715
Christine B. Turley is an academic researcher from University of South Carolina. The author has contributed to research in topics: Health care & Vaccination. The author has an hindex of 10, co-authored 23 publications receiving 554 citations. Previous affiliations of Christine B. Turley include Medical University of South Carolina & University of Texas Medical Branch.
Papers
More filters
Journal ArticleDOI
Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults.
Christine B. Turley,Richard E. Rupp,Casey P. Johnson,David N. Taylor,Julie Wolfson,Lynda Tussey,Uma Kavita,Lawrence R. Stanberry,Alan Shaw +8 more
TL;DR: VAX102 was safe and induced high antibody levels to M2e at 0.3 and 1.0 μg doses and was able to induce a fourfold rise in antibody in humans, to a previously non-immunogenic, highly-conserved portion of the influenza virus.
Journal ArticleDOI
Safety and efficacy of a cytomegalovirus glycoprotein B (gB) vaccine in adolescent girls: A randomized clinical trial.
David I. Bernstein,Flor M. Munoz,S. Todd Callahan,Richard E. Rupp,Susan H. Wootton,Kathryn M. Edwards,Christine B. Turley,Christine B. Turley,Lawrence R. Stanberry,Lawrence R. Stanberry,Shital M. Patel,Monica M. McNeal,Sylvie Pichon,Cyrille Amegashie,Abbie R. Bellamy +14 more
TL;DR: The vaccine was generally well tolerated, although local and systemic adverse events were significantly more common in the vaccine group, and the efficacy did not reach conventional levels of significance.
Journal ArticleDOI
Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
Sharon E. Frey,Patricia L. Winokur,Robert A. Salata,Samer S. El-Kamary,Christine B. Turley,Emmanuel B. Walter,Christine M. Hay,Frances K. Newman,Heather Hill,Ying Zhang,Paul Chaplin,Magdalena Tary-Lehmann,Robert B. Belshe +12 more
TL;DR: A shortened dosing schedule of Bavarian Nordic's IMVAMUNE(®) (modified vaccinia Ankara vaccine against smallpox) was compared to the currently recommended 0- and 28-day schedule for non-inferiority by evaluating the magnitude and kinetics of the immune responses.
Journal ArticleDOI
Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
Robert B. Belshe,Sharon E. Frey,Irene Graham,Edwin L. Anderson,Lisa A. Jackson,Paul Spearman,Srilatha Edupuganti,Mark J. Mulligan,Nadine Rouphael,Patricia L. Winokur,Rowena J. Dolor,Christopher W. Woods,Emmanuel B. Walter,Wilbur H. Chen,Christine B. Turley,Kathryn M. Edwards,C. Buddy Creech,Heather Hill,Abbie R. Bellamy +18 more
TL;DR: The primary immunogenicity outcome was hemagglutination inhibition assay (HAI) titer against each vaccine antigen 1 month (day 28) and 6 months (day 180) after last vaccination.
Journal ArticleDOI
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules.
Romina Libster,Monica M. McNeal,Emmanuel B. Walter,Andi L. Shane,Patricia L. Winokur,Gretchen A. Cress,Andrea A. Berry,Karen L. Kotloff,Kwabena O. Sarpong,Christine B. Turley,Christopher J. Harrison,Barbara A. Pahud,Jyothi Marbin,John Dunn,Jill El-Khorazaty,Jill Barrett,Kathryn M. Edwards +16 more
TL;DR: Investigation of the noninferiority of the immune responses to the 2 licensed rotavirus vaccines when administered as a mixed schedule compared with administering a single vaccine formulation alone found mixed schedules are safe and induced comparable immune responses when compared with the licensed rotvirus vaccines given alone.